Last reviewed · How we verify
telomerase peptide vaccine GV1001
telomerase peptide vaccine GV1001 is a Biologic drug developed by Royal Liverpool University Hospital. It is currently in Phase 3 development for Metastatic non-small cell lung cancer, PD-L1 positive.
GV1001 works by stimulating an immune response against telomerase, a protein often overexpressed in cancer cells.
GV1001 works by stimulating an immune response against telomerase, a protein often overexpressed in cancer cells. Used for Metastatic non-small cell lung cancer, PD-L1 positive.
At a glance
| Generic name | telomerase peptide vaccine GV1001 |
|---|---|
| Sponsor | Royal Liverpool University Hospital |
| Target | Telomerase |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Telomerase is an enzyme that maintains telomeres, the protective caps on chromosome ends. In cancer cells, telomerase is often overexpressed, allowing these cells to divide indefinitely. GV1001, a telomerase peptide vaccine, aims to induce an immune response against telomerase, potentially slowing or stopping cancer cell growth.
Approved indications
- Metastatic non-small cell lung cancer, PD-L1 positive
Common side effects
- Injection site pain
- Fatigue
- Headache
Key clinical trials
- GV1001 Subcutaneous for the Treatment of Moderate to Severe Alzheimer's Disease(AD) (PHASE3)
- GV1001 Subcutaneous(SC) for the Treatment of Progressive Supranuclear Palsy (PSP) (PHASE2)
- Administration of GV1001 for the Treatment of Progressive Supranuclear Palsy Who Completed Study GV1001-PSP-CL2-011 (PHASE2)
- Evaluation of the Safety, Tolerability and PK Characteristics of GV1001 in Healthy Subjects (PHASE1)
- GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD) (PHASE2)
- Evaluate the Efficacy and Safety of GV1001 in Patients With Benign Prostatic Hyperplasia (BPH) (PHASE3)
- A Phase II Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With BPH (PHASE2)
- GV1001 Subcutaneous(SC) for the Treatment of Moderate Alzheimer's Disease (AD) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- telomerase peptide vaccine GV1001 CI brief — competitive landscape report
- telomerase peptide vaccine GV1001 updates RSS · CI watch RSS
- Royal Liverpool University Hospital portfolio CI
Frequently asked questions about telomerase peptide vaccine GV1001
What is telomerase peptide vaccine GV1001?
How does telomerase peptide vaccine GV1001 work?
What is telomerase peptide vaccine GV1001 used for?
Who makes telomerase peptide vaccine GV1001?
What development phase is telomerase peptide vaccine GV1001 in?
What are the side effects of telomerase peptide vaccine GV1001?
What does telomerase peptide vaccine GV1001 target?
Related
- Target: All drugs targeting Telomerase
- Manufacturer: Royal Liverpool University Hospital — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Metastatic non-small cell lung cancer, PD-L1 positive
- Compare: telomerase peptide vaccine GV1001 vs similar drugs
- Pricing: telomerase peptide vaccine GV1001 cost, discount & access